News | June 03, 2026
Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
The conference highlighted research suggesting that deuterium levels may influence key biological processes
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
